deamidation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
== Sources == This article incorporates text from a free content work. Licensed under CC BY-SA 3.0 (license statement/permission). Text taken from The State of Food and Agriculture 2019. Moving forward on food loss and waste reduction, In brief, 24, FAO, FAO.
It has also been considered a contaminant of beer due to its homofermentative production of lactic acid, an off-flavor in many styles of beer. In other styles of beer, however, lactic acid bacteria can contribute to the overall appearance, aroma, taste, and/or mouthfeel, and generally produce an otherwise pleasing sourness.
Savimbi used Jamba to augment UNITA's public image, investing heavily in local infrastructure. He opened the settlement to American and South African journalists, honed his public relations skills in frequent press conferences denouncing the MPLA, and lobbied for Western aid. Under the Reagan Doctrine, the US government opened covert channels to provide military assistance to UNITA. It repealed the Clark Amendment, which explicitly barred further CIA support for the UNITA and the FNLA, allowing the agency to resume Angolan operations. The Angolan government asserted this was "proof of the complicity there has always been between the US executive and the retrograde racist Pretoria regime" and it had "no alternative but to suspend the contacts it has had with US government envoys". In 1986, Savimbi visited Washington, where he met with American officials and was promised military hardware valued at about 10 million dollars, including FIM-92 Stinger surface-to-air missiles and BGM-71 TOW anti-tank missiles. The US also pledged to continue its support for UNITA even if it lost the umbrella of protection conferred by the SADF presence in southern Angola. At the US government's request, South Africa began lending UNITA a greater degree of material assistance, and aided the CIA in the acquisition of untraceable arms for the Angolan insurgents. The CIA was interested in acquiring Soviet and Eastern European arms for UNITA, as they could be easily passed off as weapons individual partisans had captured from FAPLA.
Sources: en.wikipedia.org
== Episode 6: Deja Vu == Matt Lee is a 20-year-old college student who suffers from fainting spells that only occur when he has a sense of Deja Vu, these fainting spells at times can cause his heart to stop all together. Matt states that when he was around 19, one day he just started feeling very light headed and had a sense of Deja Vu then shortly after he blacked out. When he woke back up and realized he had blacked out, he immediately went to the hospital, the next time he fainted had flatlined. Specifically his symptoms include a sense of tingling in his head that is followed by light-headedness, nausea, heart palpitations, loss of control, and then finally the Deja Vu before he faints. Matt is extremely afraid that these random fainting episodes could happen at any time during the day and he might not have someone to help him out, because of these he stays at home as much as he could. He expresses his disappointment in not being able to follow his goals in wanting to study computer science and wanting to find a cure or treatment that would allow him to be “free” again. Matt was admitted into Johns Hopkins Hospital for in depth testing of all his symptoms, the only definitive diagnosis known is the fact that Matt is experiencing Syncope. Syncope are essentially fainting spells that are caused by a decrease of blood reaching the brain, the only question is what is causing the decreased blood flow along with the other symptoms.
Carroll, J. T. (1975). Ireland in the War Years 1939–1945. David and Charles. ISBN 9780844805658. Coogan, Tim Pat (1993). De Valera: Long Fellow, Long Shadow. London: Hutchinson. ISBN 9780091750305. published as Eamon de Valera: The Man Who Was Ireland (New York, 1993) Coogan, Tim Pat (1990). Michael Collins. Hutchinson. ISBN 0-09-174106-8. Corcoran, Donal. "Public policy in an emerging state: The Irish Free State 1922-25." Irish Journal of Public Policy 1.1 (2009). online Dwyer, T. Ryle (2006). Big Fellow, Long Fellow: A Joint Biography of Collins and De Valera. Gill Books. ISBN 0717140849. excerpt and text search Dwyer, T. Ryle (1982). De Valera's Finest Hour 1932–59. Fanning, Ronan. Éamon de Valera: A Will to Power (2016) Foster, R. F. Modern Ireland, 1600-1972 (1989) online Girvin, Brian. "Beyond Revisionism? Some Recent Contributions to the Study of Modern Ireland." The English Historical Review 124#506, 2009, pp. 94–107. online Gwynn, Denis. The Irish Free State, 1922-1927 (Macmillan 1928); detailed coverage.online Keown, Gerard. First of the Small Nations: The Beginnings of Irish Foreign Policy in the Inter-war Years, 1919-1932 (Oxford University Press, 2016). online Kissane, Bill. "Eamon De Valera and the Survival of Democracy in Inter-War Ireland". Journal of Contemporary History (2007). 42 (2): 213–226. online Lee, J. J. Ireland, 1912-1985: politics and society (Cambridge University Press, 1989) online. McCardle, Dorothy (January 1999). The Irish Republic. Wolfhound Press. ISBN 0-86327-712-8. O'Halpin, Eunan.
Application of a tourniquet to the bitten limb is generally not recommended. There is no convincing evidence that it is an effective first-aid tool as ordinarily applied. Tourniquets have been found to be completely ineffective in the treatment of Crotalus durissus bites, but some positive results have been seen with properly applied tourniquets for cobra venom in the Philippines. Uninformed tourniquet use is dangerous since reducing or cutting off circulation can lead to gangrene, which can be fatal. The use of a compression bandage is generally as effective, and much safer. Cutting open the bitten area, an action often taken before suction, is not recommended since it causes further damage and increases the risk of infection; the subsequent cauterization of the area with fire or silver nitrate (also known as infernal stone) is also potentially threatening. Sucking out venom, either by mouth or with a pump, does not work and may harm the affected area directly. Suction started after three minutes removes a clinically insignificant quantity—less than one-thousandth of the venom injected—as shown in a human study. In a study with pigs, suction not only caused no improvement but led to necrosis in the suctioned area. Suctioning by mouth presents a risk of further poisoning through the mouth's mucous tissues. The helper may also release bacteria into the person's wound, leading to infection.
Tachykinin peptides are also involved in inflammation, and tachykinin receptor antagonists have been researched for use in treating inflammatory conditions such as asthma and irritable bowel syndrome. The main use for which these antagonist drugs have been applied so far, however, is as antiemetics, in both human and veterinary medicine. Examples of tachykinin antagonists include:
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.